The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Soleno Therapeutics Inc (NASDAQ: SLNO) closed at $47.17 in the last session, up 1.88% from day before closing price of $46.3. In other words, the price has increased by $1.88 from its previous closing price. On the day, 1.77 million shares were traded. SLNO stock price reached its highest trading level at $47.93 during the session, while it also had its lowest trading level at $46.01.
Ratios:
We take a closer look at SLNO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.88 and its Current Ratio is at 16.08. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Wolfe Research on November 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $75.
On October 07, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $125.
On August 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $123.Wells Fargo initiated its Overweight rating on August 20, 2025, with a $123 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 2533501696 and an Enterprise Value of 2087230848. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.68 while its Price-to-Book (P/B) ratio in mrq is 5.12. Its current Enterprise Value per Revenue stands at 21.153 whereas that against EBITDA is -25.374.
Stock Price History:
The Beta on a monthly basis for SLNO is -3.12, which has changed by 0.027668834 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is -9.46%, while the 200-Day Moving Average is calculated to be -29.85%.
Shares Statistics:
According to the various share statistics, SLNO traded on average about 1.72M shares per day over the past 3-months and 1154610 shares per day over the past 10 days. A total of 53.70M shares are outstanding, with a floating share count of 49.27M. Insiders hold about 8.27% of the company’s shares, while institutions hold 117.17% stake in the company. Shares short for SLNO as of 1765756800 were 9252492 with a Short Ratio of 5.37, compared to 1763078400 on 9730583. Therefore, it implies a Short% of Shares Outstanding of 9252492 and a Short% of Float of 19.639999.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 13.0 analysts currently analyzing and rating the stock of Soleno Therapeutics Inc (SLNO).The consensus estimate for the next quarter is $0.68, with high estimates of $1.08 and low estimates of $0.23.
Analysts are recommending an EPS of between $0.74 and -$0.24 for the fiscal current year, implying an average EPS of $0.19. EPS for the following year is $4.11, with 13.0 analysts recommending between $5.78 and $1.78.
Revenue Estimates
For the next quarter, 11 analysts are estimating revenue of $90.17M. There is a high estimate of $108.18M for the next quarter, whereas the lowest estimate is $73.8M. Based on 11 analysts’ estimates, the company’s revenue will be $465.69M in the next fiscal year. The high estimate is $563.14M and the low estimate is $351.6M.
